文献速递哮喘

儿童哮喘控制不佳的最佳升级治疗:个体参与者数据系统综述与网络荟萃分析

Best step-up treatments for children with uncontrolled asthma: a systematic review and network meta-analysis of individual participant data.
PubMed 文献 · Eur Respir J · 2023-12-21

该研究纳入29项试验的个体参与者数据和19项试验的聚合数据,评估18岁以下使用吸入性糖皮质激素(ICS)仍未控制的哮喘患者的药物升级方案。与低剂量ICS相比,中剂量ICS+长效β2受体激动剂(LABA)的急性发作风险最低(OR 0.44,95%CrI 0.19-0.90),且一秒用力呼气容积改善(均差0.71,95%CrI 0.35-1.06)。白三烯受体拮抗剂(LTRA)为最不推荐方案,哮喘控制无显著差异。

要点

  • 低剂量ICS控制不佳的儿童/青少年建议升级为中剂量ICS+LABA。
  • 中剂量ICS+LABA较低剂量ICS显著降低急性发作风险并改善肺功能。
  • LTRA为最不推荐的治疗选择,哮喘控制无显著差异。

核心结论

  • 低剂量ICS未控制的儿童/青少年应推荐升级为中剂量ICS+LABA以降低急性发作风险并改善肺功能。

研究设计与样本

  • 系统综述与个体参与者数据网络荟萃分析,检索MEDLINE等数据库(2014年7月1日至2023年5月5日)。
  • 纳入144项符合条件的随机对照试验,获得29项试验的个体参与者数据和19项试验的聚合数据。
  • 研究对象为18岁以下筛查时使用任意剂量ICS单药仍未控制的哮喘患者。

主要发现

  • 与低剂量ICS相比,中剂量ICS+LABA的急性发作风险最低(OR 0.44,95%CrI 0.19-0.90)。
  • 中剂量ICS+LABA较低剂量ICS改善一秒用力呼气容积(均差0.71,95%CrI 0.35-1.06)。
  • LTRA为最不推荐的治疗方案。
  • 各治疗方案间哮喘控制无显著差异。

关键数值与推荐

  • 主要结局为急性发作和哮喘控制。
  • 评估干预包括低/中/高剂量ICS、ICS+LABA、ICS+LTRA、LTRA单药、茶碱和安慰剂。

临床怎么用

  • 对低剂量ICS未控制的儿童/青少年,优先考虑升级为中剂量ICS+LABA。
  • 不推荐将LTRA作为首选的升级治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is uncertainty about the best treatment option for children/adolescents with uncontrolled asthma despite inhaled corticosteroids (ICS) and international guidelines make different recommendations. We evaluated the pharmacological treatments to reduce asthma exacerbations and symptoms in uncontrolled patients age <18 years on ICS. METHODS: We searched MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Embase, Web of Science, National Institute for Health and Care Excellence Technology Appraisals, National Institute for Health and Care Research Health Technology Assessment series, World Health Organization International Clinical Trials Registry, conference abstracts and internal clinical trial registers (1 July 2014 to 5 May 2023) for randomised controlled trials of participants age <18 years with uncontrolled asthma on any ICS dose alone at screening. Studies before July 2014 were retrieved from previous systematic reviews/contact with authors. Patients had to be randomised to any dose of ICS alone or combined with long-acting β2-agonists (LABA) or combined with leukotriene receptor antagonists (LTRA), LTRA alone, theophylline or placebo. Primary outcomes were exacerbation and asthma control. The interventions evaluated were ICS (low/medium/high dose), ICS+LABA, ICS+LTRA, LTRA alone, theophylline and placebo. RESULTS: Of the 4708 publications identified, 144 trials were eligible. Individual participant data were obtained from 29 trials and aggregate data were obtained from 19 trials. Compared with ICS Low, ICS Medium+LABA was associated with the lowest odds of exacerbation (OR 0.44, 95% credibility interval (95% CrI) 0.19-0.90) and with an increased forced expiratory volume in 1 s (mean difference 0.71, 95% CrI 0.35-1.06). Treatment with LTRA was the least preferred. No apparent differences were found for asthma control. CONCLUSIONS: Uncontrolled children/adolescents on low-dose ICS should be recommended a change to medium-dose ICS+LABA to reduce the risk for exacerbation and improve lung function.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Cividini, Sinha, Donegan, et al. Best step-up treatments for children with uncontrolled asthma: a systematic review and network meta-analysis of individual participant data. Eur Respir J. 2023. PMID: 37945034. doi:10.1183/13993003.01011-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。